Recombinant Human IL10RA(His22-Asn235) was expressed in HEK293.
Predicted N Terminal:
Lyophilized from a 0.2 μm filtered solution in PBS.
Measured by its ability to inhibit IL-10-dependent proliferation of MC/9‑2 mouse mast cells. Thompson-Snipes, L. et al. (1991) J. Exp. Med. 173:507. The ED50 for this effect is typically 0.05‑0.25 µg/mL in the presence of 2 ng/mL of Recombinant Human IL‑10.
Predicted Molecular Mass: 24 kDa;SDS-PAGE: 38-52 kDa, reducing conditions
<0.10 EU per 1 μg of the protein by the LAL method.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in PBS.